Status:
COMPLETED
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborating Sponsors:
Myeloproliferative Disorders-Research Consortium
National Cancer Institute (NCI)
Conditions:
Myeloproliferative Disease
Myelofibrosis
Eligibility:
All Genders
18+ years
Brief Summary
Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide no...
Eligibility Criteria
Inclusion
- Patients are to be registered to this study if they meet the eligibility criteria for one of the MPD-RC treatment protocols linked to this study.
- Patients diagnosed with the following Myeloproliferative disorders including: polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia (ET) who are participating in treatment protocols of the MPD-RC are eligible.
- Patients must have signed an informed consent to participate in a Myeloproliferative Disorders Research Consortium (MPD-RC) treatment study to which this protocol is a companion study. The subject must also have signed a consent to participate in this mandatory companion study.
Exclusion
- See inclusion criteria.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 20 2018
Estimated Enrollment :
592 Patients enrolled
Trial Details
Trial ID
NCT00665067
Start Date
April 1 2007
End Date
July 20 2018
Last Update
December 13 2018
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Scottsdale, Arizona, United States, 85259
2
The Palo Alto Clinic
Palo Alto, California, United States, 94301
3
Georgetown University
Washington D.C., District of Columbia, United States, 20057
4
Emory Hospital
Atlanta, Georgia, United States, 30322